NCT06660719View on ClinicalTrials.gov

Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care

PHASE3RecruitingINTERVENTIONAL
Enrollment

852

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

March 30, 2027

Conditions
Ischemic Stroke
Interventions
DRUG

SP-8203

SP-8203 80 mg will be intravenously administered as 40 mg/dose twice daily (intervals of 12 hours)

DRUG

Placebo

Placebo will be intravenously administered twice daily (intervals of 12 hours)

Trial Locations (2)

44033

RECRUITING

Ulsan University Hospital, Ulsan

49201

RECRUITING

Dong-A University Hospital, Busan

All Listed Sponsors
lead

Shin Poong Pharmaceutical Co. Ltd.

INDUSTRY